BCTX · Briacell Therapeutics
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. The company is headquartered in West Vancouver, Canada.
Market Cap
28.64M
52 Wk Range
$2.60 - $13.09
Previous Close
$3.28
Open
$3.29
Volume
63,881
Day Range
$3.15 - $3.30
Enterprise Value
7.881M
Cash
20.54M
Avg Qtr Burn
-5.959M
Insider Ownership
0.14%
Institutional Own.
5.35%
Qtr Updated
Jul 31st 2026
